Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

Trial Details

NCT ID
NCT06881784
Phase
PHASE3
Sponsor
Revolution Medicines, Inc.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • daraxonrasib
  • docetaxel
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Loma Linda, California, United States|34.04835,-117.26115
  • Long Beach, California, United States|33.76696,-118.18923
  • Orange, California, United States|33.78779,-117.85311
  • Colorado Springs, Colorado, United States|38.83388,-104.82136

Key Eligibility Criteria

  • At least 18 years old and has provided informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Pathologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy.
  • Measurable disease per RECIST v1.1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →